Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 8% and 3.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SQZ Biotechnologies Company (SQZ) delivered earnings and revenue surprises of -11.11% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Synlogic, Inc. (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 12.50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 10.34% and 12.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
– Three clinical data readouts across three programs expected in H2 2022 – – PKU Phase 3 readiness activities underway for planned start in H1 2023 – – ...